Nuances in the Management of Older People With Multiple Myeloma

Charlotte Pawlyn, Francesca Gay, Alessandra Larocca, Vivek Roy, Sikander Ailawadhi

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Multiple myeloma is a disease of the elderly, with about a third of patients at diagnosis older than 75 years of age. Yet, the population of elderly patients is heterogeneous: older patients are more likely to have comorbidities and frailties complicating both their initial diagnosis and subsequent management, but these are not consistent across the group. Furthermore, patients with comorbidities and frailty are generally underrepresented in clinical trials. Despite the survival of myeloma patients increasing following the introduction of novel agents, older patients continue to have worse outcomes with increased treatment-related toxicity. Treatment tolerability is not defined by age alone, rather a combination of age, physical function, cognitive function, and comorbidities. These factors all influence patients’ tolerability of treatment and therefore treatment efficacy and should also be considered when reviewing the results of clinical trials. It is the nuances of determining how these factors interact that should influence initial treatment and ongoing management decisions and these will be discussed here.

Original languageEnglish (US)
Pages (from-to)241-251
Number of pages11
JournalCurrent Hematologic Malignancy Reports
Volume11
Issue number3
DOIs
StatePublished - Jun 1 2016

Fingerprint

Multiple Myeloma
Comorbidity
Clinical Trials
Proxy
Therapeutics
Cognition
Survival
Population

Keywords

  • Elderly
  • Multiple myeloma
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Nuances in the Management of Older People With Multiple Myeloma. / Pawlyn, Charlotte; Gay, Francesca; Larocca, Alessandra; Roy, Vivek; Ailawadhi, Sikander.

In: Current Hematologic Malignancy Reports, Vol. 11, No. 3, 01.06.2016, p. 241-251.

Research output: Contribution to journalReview article

Pawlyn, Charlotte ; Gay, Francesca ; Larocca, Alessandra ; Roy, Vivek ; Ailawadhi, Sikander. / Nuances in the Management of Older People With Multiple Myeloma. In: Current Hematologic Malignancy Reports. 2016 ; Vol. 11, No. 3. pp. 241-251.
@article{e99e6ce347ea4da687cac5211b5b09d7,
title = "Nuances in the Management of Older People With Multiple Myeloma",
abstract = "Multiple myeloma is a disease of the elderly, with about a third of patients at diagnosis older than 75 years of age. Yet, the population of elderly patients is heterogeneous: older patients are more likely to have comorbidities and frailties complicating both their initial diagnosis and subsequent management, but these are not consistent across the group. Furthermore, patients with comorbidities and frailty are generally underrepresented in clinical trials. Despite the survival of myeloma patients increasing following the introduction of novel agents, older patients continue to have worse outcomes with increased treatment-related toxicity. Treatment tolerability is not defined by age alone, rather a combination of age, physical function, cognitive function, and comorbidities. These factors all influence patients’ tolerability of treatment and therefore treatment efficacy and should also be considered when reviewing the results of clinical trials. It is the nuances of determining how these factors interact that should influence initial treatment and ongoing management decisions and these will be discussed here.",
keywords = "Elderly, Multiple myeloma, Treatment",
author = "Charlotte Pawlyn and Francesca Gay and Alessandra Larocca and Vivek Roy and Sikander Ailawadhi",
year = "2016",
month = "6",
day = "1",
doi = "10.1007/s11899-016-0323-4",
language = "English (US)",
volume = "11",
pages = "241--251",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - Nuances in the Management of Older People With Multiple Myeloma

AU - Pawlyn, Charlotte

AU - Gay, Francesca

AU - Larocca, Alessandra

AU - Roy, Vivek

AU - Ailawadhi, Sikander

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Multiple myeloma is a disease of the elderly, with about a third of patients at diagnosis older than 75 years of age. Yet, the population of elderly patients is heterogeneous: older patients are more likely to have comorbidities and frailties complicating both their initial diagnosis and subsequent management, but these are not consistent across the group. Furthermore, patients with comorbidities and frailty are generally underrepresented in clinical trials. Despite the survival of myeloma patients increasing following the introduction of novel agents, older patients continue to have worse outcomes with increased treatment-related toxicity. Treatment tolerability is not defined by age alone, rather a combination of age, physical function, cognitive function, and comorbidities. These factors all influence patients’ tolerability of treatment and therefore treatment efficacy and should also be considered when reviewing the results of clinical trials. It is the nuances of determining how these factors interact that should influence initial treatment and ongoing management decisions and these will be discussed here.

AB - Multiple myeloma is a disease of the elderly, with about a third of patients at diagnosis older than 75 years of age. Yet, the population of elderly patients is heterogeneous: older patients are more likely to have comorbidities and frailties complicating both their initial diagnosis and subsequent management, but these are not consistent across the group. Furthermore, patients with comorbidities and frailty are generally underrepresented in clinical trials. Despite the survival of myeloma patients increasing following the introduction of novel agents, older patients continue to have worse outcomes with increased treatment-related toxicity. Treatment tolerability is not defined by age alone, rather a combination of age, physical function, cognitive function, and comorbidities. These factors all influence patients’ tolerability of treatment and therefore treatment efficacy and should also be considered when reviewing the results of clinical trials. It is the nuances of determining how these factors interact that should influence initial treatment and ongoing management decisions and these will be discussed here.

KW - Elderly

KW - Multiple myeloma

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84962167099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962167099&partnerID=8YFLogxK

U2 - 10.1007/s11899-016-0323-4

DO - 10.1007/s11899-016-0323-4

M3 - Review article

C2 - 27038805

AN - SCOPUS:84962167099

VL - 11

SP - 241

EP - 251

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 3

ER -